Therefore, it may be preferable to administer imatinib first to determine the response regardless of the size of the tumour before proceeding to surgery; however, it may be necessary to check for KIT mutations before treatment, as there may be a small number of tumours with PDGFRα mutations or wild-type that do not respond well to imatinib. This evidence concerns the gene PDGFRA and neoplasm.